{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T01:34:42Z","timestamp":1775784882679,"version":"3.50.1"},"reference-count":16,"publisher":"American Society of Hematology","issue":"2","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,1,26]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Although patients with bronchus-associated lymphoid tissue (BALT) lymphoma show an indolent clinical course, appropriate disease management at diagnosis is not well defined. This study aimed to compare 3 treatment strategies for patients with BALT lymphoma: active surveillance, systemic chemotherapy or immunotherapy at diagnosis, or complete surgical resection at diagnosis. We conducted a retrospective study of all patients with new diagnoses of marginal zone lymphoma (MZL) involving the lung who were treated at the Memorial Sloan Kettering Cancer Center between 1995 and 2017. Primary BALT lymphoma was defined as disease confined to the lungs and adjacent lymph nodes. Active surveillance was defined as a documented observation plan and \u22653 months of follow-up before initiating treatment. Overall survival (OS) and event-free survival (EFS) were compared between treatment groups. We reviewed 200 consecutive patients with MZL involving the lung; 123 met the inclusion criteria and were managed by active surveillance (47%), complete surgical resection (41%), or systemic chemotherapy or immunotherapy (11%). With a median follow-up of &amp;gt;60 months, surgical resection was associated with a superior EFS compared with active surveillance and systemic treatment (6-year EFS: 74% vs 65% vs 62%, respectively; P = .013). Larger lesions and thrombocytopenia were associated with shorter EFS. All groups had excellent OS at 6 years (93%), albeit with a slight superiority for surgical resection (100%) over active surveillance (91%) and systemic treatment (76%) (P = .024). BALT lymphoma is an indolent disease that can often be managed expectantly and not require therapy for many years.<\/jats:p>","DOI":"10.1182\/bloodadvances.2020003213","type":"journal-article","created":{"date-parts":[[2021,1,15]],"date-time":"2021-01-15T16:31:58Z","timestamp":1610728318000},"page":"345-351","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":17,"title":["Active surveillance of primary extranodal marginal zone lymphoma of bronchus-associated lymphoid tissue"],"prefix":"10.1182","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7883-289X","authenticated-orcid":false,"given":"Erel","family":"Joffe","sequence":"first","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center, New York, NY;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Leyfman","sequence":"additional","affiliation":[{"name":"Penn State College of Medicine, Hershey, PA; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3315-4538","authenticated-orcid":false,"given":"Esther","family":"Drill","sequence":"additional","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center, New York, NY;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sridevi","family":"Rajeeve","sequence":"additional","affiliation":[{"name":"Icahn School of Medicine at Mount Sinai, New York, NY"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1403-6883","authenticated-orcid":false,"given":"Andrew D.","family":"Zelenetz","sequence":"additional","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center, New York, NY;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. Lia","family":"Palomba","sequence":"additional","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center, New York, NY;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Craig H.","family":"Moskowitz","sequence":"additional","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center, New York, NY;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carol","family":"Portlock","sequence":"additional","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center, New York, NY;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3001-4898","authenticated-orcid":false,"given":"Ariela","family":"Noy","sequence":"additional","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center, New York, NY;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven M.","family":"Horwitz","sequence":"additional","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center, New York, NY;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John F.","family":"Gerecitano","sequence":"additional","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center, New York, NY;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alison","family":"Moskowitz","sequence":"additional","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center, New York, NY;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9500-1804","authenticated-orcid":false,"given":"Paul","family":"Hamlin","sequence":"additional","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center, New York, NY;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew J.","family":"Matasar","sequence":"additional","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center, New York, NY;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anita","family":"Kumar","sequence":"additional","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center, New York, NY;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9036-9463","authenticated-orcid":false,"given":"Connie L.","family":"Batlevi","sequence":"additional","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center, New York, NY;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anas","family":"Younes","sequence":"additional","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center, New York, NY;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David J.","family":"Straus","sequence":"additional","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center, New York, NY;"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","published-online":{"date-parts":[[2021,1,15]]},"reference":[{"issue":"4","key":"2021011522105465900_B1","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.clinimag.2008.02.030","article-title":"Pulmonary lymphoma identified as a result of low-dose CT screening for lung cancer","volume":"32","author":"Huang","year":"2008","journal-title":"Clin Imaging"},{"issue":"7","key":"2021011522105465900_B2","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1002\/1097-0142(196307)16:7<928::AID-CNCR2820160709>3.0.CO;2-H","article-title":"Pulmonary malignant lymphomas and pseudolymphomas: classification, therapy, and prognosis","volume":"16","author":"Saltzstein","year":"1963","journal-title":"Cancer"},{"issue":"4","key":"2021011522105465900_B3","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1002\/hon.2243","article-title":"A retrospective international study on primary extranodal marginal zone lymphoma of the lung (BALT lymphoma) on behalf of International Extranodal Lymphoma Study Group (IELSG)","volume":"34","author":"Sammassimo","year":"2016","journal-title":"Hematol Oncol"},{"issue":"18","key":"2021011522105465900_B4","doi-asserted-by":"crossref","first-page":"7660","DOI":"10.1002\/cam4.2683","article-title":"Clinical characteristics, diagnosis, treatment, and prognostic factors of pulmonary mucosa-associated lymphoid tissue-derived lymphoma","volume":"8","author":"Wang","year":"2019","journal-title":"Cancer Med"},{"issue":"6","key":"2021011522105465900_B5","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1007\/s00277-009-0875-7","article-title":"Pulmonary marginal zone B-cell lymphoma of MALT type\u2013what is a prognostic factor and which is the optimal treatment, operation, or chemotherapy?: Consortium for Improving Survival of Lymphoma (CISL) study","volume":"89","author":"Oh","year":"2010","journal-title":"Ann Hematol"},{"issue":"1","key":"2021011522105465900_B6","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.jtcvs.2017.03.043","article-title":"Treatment outcomes in patients with extranodal marginal zone B-cell lymphoma of the lung","volume":"154","author":"Lee","year":"2017","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"4","key":"2021011522105465900_B7","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1016\/S0003-4975(99)01535-0","article-title":"Primary non-Hodgkin\u2019s lymphoma of the lung","volume":"69","author":"Ferraro","year":"2000","journal-title":"Ann Thorac Surg"},{"issue":"9383","key":"2021011522105465900_B8","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/S0140-6736(03)14110-4","article-title":"Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial","volume":"362","author":"Ardeshna","year":"2003","journal-title":"Lancet"},{"issue":"3","key":"2021011522105465900_B9","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1200\/JCO.1997.15.3.1110","article-title":"Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d\u2019Etude des Lymphomes Folliculaires. Groupe d\u2019Etude des Lymphomes de l\u2019Adulte","volume":"15","author":"Brice","year":"1997","journal-title":"J Clin Oncol"},{"key":"2021011522105465900_B10","first-page":"3633","article-title":"Does MALT lymphoma of the lung require immediate treatment? An analysis of 11 untreated cases with long-term follow-up","volume":"27","author":"Troch","year":"2007","journal-title":"Anticancer Res"},{"issue":"7-8","key":"2021011522105465900_B11","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.diii.2014.05.002","article-title":"Imaging criteria for assessing tumour response: RECIST, mRECIST, Cheson","volume":"95","author":"Fournier","year":"2014","journal-title":"Diagn Interv Imaging"},{"key":"2021011522105465900_B12","doi-asserted-by":"crossref","DOI":"10.1001\/978-1-57947-888-9","volume-title":"Guides to the Evaluation of Permanent Impairment","author":"Rondinelli","year":"2008","edition":"6th ed"},{"issue":"8","key":"2021011522105465900_B13","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1097\/00000478-200108000-00003","article-title":"Pathologic and clinical features of primary pulmonary extranodal marginal zone B-cell lymphoma of MALT type","volume":"25","author":"Kurtin","year":"2001","journal-title":"Am J Surg Pathol"},{"issue":"4","key":"2021011522105465900_B14","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1002\/hon.2039","article-title":"Extranodal marginal zone B-cell lymphoma of the lung: experience with fludarabine and mitoxantrone-containing regimens","volume":"31","author":"Zinzani","year":"2013","journal-title":"Hematol Oncol"},{"issue":"6","key":"2021011522105465900_B15","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1183\/09031936.00039309","article-title":"Clinical characteristics and prognostic factors of pulmonary MALT lymphoma","volume":"34","author":"Borie","year":"2009","journal-title":"Eur Respir J"},{"key":"2021011522105465900_B16","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.lungcan.2019.04.004","article-title":"Clinical features and outcomes of pulmonary lymphoma: a single center experience of 180 cases","volume":"132","author":"Zhang","year":"2019","journal-title":"Lung Cancer"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/5\/2\/345\/1797503\/advancesadv2020003213.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/5\/2\/345\/1797503\/advancesadv2020003213.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,15]],"date-time":"2021-01-15T23:19:16Z","timestamp":1610752756000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/5\/2\/345\/474919\/Active-surveillance-of-primary-extranodal-marginal"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,15]]},"references-count":16,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,1,26]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2020003213","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,15]]}}}